enGene Therapeutics Inc (ENGN)

NASD · Healthcare · Biotechnology · Canada

enGene Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

enGene Therapeutics is a clinical-stage biotechnology company developing non-viral genetic medicines for mucosal tissue delivery. Its lead product candidate, detalimogene, is designed to treat non-muscle invasive bladder cancer patients unresponsive to standard therapies. The company utilizes its proprietary DDX gene delivery platform to enable localized therapeutic delivery to affected tissues.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the enGene Therapeutics Inc stock.

Our verdict on ENGN

Not valued: We cannot value this company yet.

Browse

• Stocks in Canada
• Healthcare stocks in Canada

Peers in Biotechnology

• Vertex Pharmaceuticals Inc (VRTX)
• Regeneron Pharmaceuticals Inc (REGN)
• Moderna Inc (MRNA)
• Argen X SE ADR (ARGX)
• Revolution Medicines Inc (RVMD)
• Royalty Pharma plc (RPRX)
• BeOne Medicines Ltd ADR (ONC)
• Genmab ADR (GMAB)

All 598 Biotechnology stocks

Cheaper than ENGN in Biotechnology

• Arbutus Biopharma Corp (ABUS): undervalued, 79% margin of safety
• Lakefront Biotherapeutics NV ADR (LKFT): undervalued, 77% margin of safety
• CorMedix Inc (CRMD): undervalued, 74% margin of safety
• MeiraGTx Holdings plc (MGTX): undervalued, 73% margin of safety
• Bicycle Therapeutics Plc ADR (BCYC): undervalued, 71% margin of safety
• Innoviva Inc (INVA): undervalued, 71% margin of safety

134 more in this industry show a wider margin of safety.

Is ENGN undervalued or overvalued?

We do not publish a verdict on ENGN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of ENGN?

We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.